Oct 20, 2026 07:30AM
Aug 11, 2026 07:30AM
Jul 2, 2026 04:19AM
Jun 29, 2026 07:01AM
Jun 29, 2026 07:00AM
Jun 8, 2026 07:31AM
Jun 8, 2026 07:30AM Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
May 12, 2026 04:05PM
May 12, 2026 06:00AM
Apr 28, 2026 07:30AM
Mar 24, 2026 10:28AM
Mar 24, 2026 07:30AM
Feb 26, 2026 04:01PM
Feb 26, 2026 04:01PM Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Jan 12, 2026 07:00AM
Jan 12, 2026 07:00AM
Nov 13, 2025 05:10PM
Nov 12, 2025 04:01PM
Nov 6, 2025 07:30AM
Oct 9, 2025 07:01AM
Oct 9, 2025 07:00AM Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
Oct 3, 2025 06:43AM
Aug 14, 2025 08:01AM
Aug 11, 2025 04:10PM
Jul 1, 2025 08:21AM
Jun 30, 2025 04:02PM
Jun 30, 2025 04:01PM
Jun 17, 2025 09:17AM Craig-Hallum Starts Neurogene (NGNE) at Buy
Jun 5, 2025 12:44PM
May 19, 2025 12:29PM
May 16, 2025 03:35AM
May 9, 2025 07:30AM
Apr 28, 2025 05:00PM
Apr 2, 2025 04:01PM
Apr 2, 2025 04:01PM Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
Mar 24, 2025 04:10PM
Nov 25, 2024 06:47AM
Nov 20, 2024 04:54PM
Nov 19, 2024 04:02PM
Nov 19, 2024 11:07AM
Nov 18, 2024 05:25PM
Nov 18, 2024 06:45AM Neurogene (NGNE) Provides Update on NGN-401 Gene Therapy Trial
Nov 18, 2024 06:45AM
Nov 11, 2024 04:01PM
Nov 11, 2024 04:01PM
Aug 14, 2024 10:14AM
Aug 9, 2024 07:30AM
Aug 7, 2024 07:30AM
Aug 7, 2024 07:30AM Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
Jul 12, 2024 07:49AM

335,343 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All